To see all protocols that comply with the WHO Essential Medicine List 

Check for clinical trials in this patient group. Link to Australian Clinical Trials website

Multiple formulations: There are two formulations of olaparib available - tablets and capsules - which are not interchangeable and are different strengths and doses. This protocol is for treatment with olaparib tablets only. Read more about transitioning from olaparib capsules to tablets.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

25 May 2020